Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Signs On to Buy More EST Antibodies from MorphoSys

NEW YORK, Jan. 8 — MorphoSys said Tuesday that it would expand its drug target identification and validation partnership with Cambridge, Mass.-based Biogen.

 

Under the two companies' initial agreement, inked one year ago, MorphoSys provides Biogen with research antibodies against expressed sequence tags for drug target validation. The new agreement increases the number of ESTs in the deal, and allows Biogen access to MorphoSys' new HuCAL GOLD library.

Through the old partnership, Biogen paid MorphoSys an upfront technology access fee and for use of the HuCAL technology. Biogen also agreed to make milestone and royalty payments for any antibody-based therapeutics.

 

By this updated agreement, MorphoSys will receive additional research and licensing payments. Financial details were not disclosed.

 

Munich-based MorphoSys develops technologies for synthetic antibody production and produces human antibodies for use in drug development.

 

Biogen will be the first partner to access this version of the MorphoSys library, said the company.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.